# Pharmacokinetics of Rivaroxaban After Bariatric Surgery

> **NCT04180436** · PHASE1 · COMPLETED · sponsor: **University Hospital, Brest** · enrollment: 67 (actual)

## Conditions studied

- Bariatric Surgery
- Morbid Obesity

## Interventions

- **DRUG:** rivaroxaban 20 mg once daily 8 days

## Key facts

- **NCT ID:** NCT04180436
- **Lead sponsor:** University Hospital, Brest
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-15
- **Primary completion:** 2022-06-21
- **Final completion:** 2022-06-27
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2025-12-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04180436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04180436, "Pharmacokinetics of Rivaroxaban After Bariatric Surgery". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04180436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*